FBP1在癌症中的研究进展

李晓涛; 王海峰; 王剑松

doi:10.12259/j.issn.2095-610X.S20211237

FBP1在癌症中的研究进展

doi: 10.12259/j.issn.2095-610X.S20211237

昆明医科大学第二附属医院泌尿外科/云南省泌尿系统疾病临床医学中心，云南昆明　650101

基金项目: 国家自然科学基金资助项目（81960322）；云南省科技厅-昆明医科大学应用基础研究联合专项基金资助项目（202001AY070001-214）；云南省教育科学研究基金资助项目（2020J0177）

详细信息

作者简介:
李晓涛（1987～），男，云南砚山人，在读博士研究生，主要从事膀胱肿瘤临床与基础研究工作

通讯作者:
王剑松，E-mail： jiansongwangkm@126.com

中图分类号: R73
计量
- 文章访问数: 2247
- HTML全文浏览量: 1951
- PDF下载量: 119
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-15
- 刊出日期: 2021-12-25

Advances on FBP1’s Role in Malignant Tumors

Dept. of Urology，The 2nd Affiliated hospital of Kunming Medical University / Yunnan Urinary System Disease Clinical Medical Center，Kunming Yunnan 650101，China

摘要

摘要: FBP1作为糖异生过程的关键酶，控制糖异生的速率，催化1-6二磷酸果糖不可逆的水解成6-磷酸果糖和无机磷酸盐，从而能够控制糖异生速率，影响细胞糖酵解。近年来，其在癌症中的作用越来越受到重视。研究发现FBP1在多种肿瘤中表达异常，与肿瘤发生、发展及预后关系密切，这些结果对于肿瘤分子标记物、靶向药物研究、预后相关研究表现出良好的前景。
- FBP1 /
- 有氧糖酵解 /
- 瓦博格效应 /
- 癌症
Abstract: As a key enzyme in the process of gluconeogenesis, FBP1 controls the rate of gluconeogenesis and catalyzes the irreversible hydrolysis of fructose 1-6 diphosphate into fructose 6-phosphate and inorganic phosphate, thereby controlling the rate of gluconeogenesis and affecting cellular glycolysis. In recent years, its role in malignant tumors has attracted more and more attention. Studies have found that FBP1 is abnormally expressed in a variety of tumors and is closely related to tumor occurrence and prognosis. These results show a good prospect for tumor molecular markers, targeted drug research, and prognosis-related research.
- FBP1 /
- Aerobic glycolysis /
- Warburg effect /
- Cancer

HTML全文

参考文献(36)

[1]	Wang H,Naghavi M,Allen C,et al. Global,regional,and national life expectancy,all-cause mortality,and cause-specific mortality for 249 causes of death,1980-2015:A systematic analysis for the global burden of disease study 2015[J]. Lancet,2016,388(10053):1459-1544. doi: 10.1016/S0140-6736(16)31012-1
[2]	Sung H,Ferlay J,Siegel R,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA-A Cancer Journal For Clinicians,2021,70(4):1-41.
[3]	Ke H,Liang J,Zhang Y,et al. Conformational transition of fructose-1,6-bisphosphatase:Structure comparison between the AMP complex (T form) and the fructose 6-phosphate complex (R form)[J]. Biochemistry,1991,30(18):4412-4420. doi: 10.1021/bi00232a007
[4]	Moon S,Kim J,Han J,et al. Novel compound heterozygous mutations in the fructose-1,6-bisphosphatase gene cause hypoglycemia and lactic acidosis[J]. Metablism,2011,60(1):107-113. doi: 10.1016/j.metabol.2009.12.021
[5]	Gonzales P,Pisitkun T,Hoffert J,et al. Large-scale proteomics and phosphoproteomics of urinary exosomes[J]. J Am Soc Nephrol,2009,20(2):363-379. doi: 10.1681/ASN.2008040406
[6]	Consortium T U. UniProt:A worldwide hub of protein knowledge[J]. Nucleic Acids Research,2019,47(1):D506-D515. doi: 10.1093/nar/gky1049
[7]	Yánez A,Nualart F,Droppelmann C,et al. Broad expression of fructose-1,6-bisphosphatase and phosphoenolpyruvate carboxykinase provide evidence for gluconeogenesis in human tissues other than liver and kidney[J]. Journal of Cellular Physiology,2003,197(2):189-197. doi: 10.1002/jcp.10337
[8]	X L,X W,J Z,et al. Warburg effect revisited:An epigenetic link between glycolysis and gastric carcinogenesis[J]. Oncogene,2010,29(3):442-450. doi: 10.1038/onc.2009.332
[9]	Li J,Wang Y,Li Q G,et al. Downregulation of FBP1 promotes tumor metastasis and indicates poor prognosis in gastric cancer via regulating epithelial-mesenchymal transition[J]. PLoS One,2016,11(12):1-15.
[10]	Yu J,Li J,Chen Y,et al. Snail Enhances glycolysis in the epithelial-mesenchymal transition process by targeting FBP1 in gastric cancer[J]. Cell Physiol Biochem,2017,43(1):31-38. doi: 10.1159/000480314
[11]	Li B,Qiu B,Lee D S,et al. Fructose-1,6-bisphosphatase opposes renal carcinoma progression[J]. Nature,2014,513(7517):251-255. doi: 10.1038/nature13557
[12]	洪正东,朱安义,王艳华,等. FBP1在肾透明细胞癌组织中的表达变化及意义[J]. 重庆医学,2018,47(14):44-47.
[13]	R C, X Z, G H, et al. Fructose 1, 6-bisphosphatase 1 expression reduces ¹⁸F-FDG uptake in clear cell renal cell carcinoma[J]. Contrast Media & Molecular Imaging, 2019, 2019（期?）: 1-6. R C,X Z,G H,et al. Fructose 1,6-bisphosphatase 1 expression reduces ¹⁸F-FDG uptake in clear cell renal cell carcinoma[J]. Contrast Media & Molecular Imaging,2019,2019:1-6.
[14]	Zhu Y,Shi M,Chen H,et al. NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells[J]. Oncotarget,2015,6(25):21443-21451. doi: 10.18632/oncotarget.4167
[15]	Chen L Y,Cheng C S,Qu C,et al. CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer[J]. Biochem Biophys Res Commun,2018,500(3):691-697. doi: 10.1016/j.bbrc.2018.04.137
[16]	Wang B,Fan P,Zhao J,et al. FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma[J]. J Exp Clin Cancer Res,2018,37(1):224-235. doi: 10.1186/s13046-018-0888-y
[17]	Jin X,Pan Y,Wang L,et al. Fructose-1,6-bisphosphatase inhibits ERK activation and bypasses gemcitabine resistance in pancreatic cancer by blocking IQGAP1-MAPK interaction[J]. Cancer Research,2017,77(16):4328-4341. doi: 10.1158/0008-5472.CAN-16-3143
[18]	C Y,S Z,H Y,et al. USP44 suppresses pancreatic cancer progression and overcomes gemcitabine resistance by deubiquitinating FBP1[J]. American Journal of Cancer Research,2019,9(8):1722-1733.
[19]	Chen M,Zhang J,Li N,et al. Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer[J]. PLoS One,2011,6(10):1-8.
[20]	J Y,C W,F Z,et al. Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect[J]. Carcinogenesis,2017,38(2):134-143.
[21]	Jin X,Pan Y,Wang L,et al. MAGE-TRIM28 complex promotes the warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation[J]. Oncogenesis,2017,6(4):1-12.
[22]	Ln Y,Zy N,L W,et al. HSF2 regulates aerobic glycolysis by suppression of FBP1 in hepatocellular carcinoma[J]. American Journal of Cancer Research,2019,9(8):1607-1621.
[23]	Liu G M,Li Q,Zhang P F,et al. Restoration of FBP1 suppressed Snail-induced epithelial to mesenchymal transition in hepatocellular carcinoma[J]. Cell Death Dis,2018,9(11):1132-1141. doi: 10.1038/s41419-018-1165-x
[24]	Zhang D,Li Z,Li T,et al. miR-517a promotes Warburg effect in HCC by directly targeting FBP1[J]. Onco Targets Ther,2018,2018(11):8025-8032.
[25]	Li Q,Wei P,Wu J,et al. The FOXC1/FBP1 signaling axis promotes colorectal cancer proliferation by enhancing the Warburg effect[J]. Oncogene,2019,38(4):483-496. doi: 10.1038/s41388-018-0469-8
[26]	Iwatsuki M,Mimori K,Yokobori T,et al. Epithelial-mesenchymal transition in cancer development and its clinical significance[J]. Cancer Science,2010,101(2):293-299. doi: 10.1111/j.1349-7006.2009.01419.x
[27]	Dong C,Yuan T,Wu Y,et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer[J]. Cancer Cell,2013,23(3):316-331. doi: 10.1016/j.ccr.2013.01.022
[28]	Li K, Ying M, Feng D, et al. Fructose-1, 6-bisphosphatase is a novel regulator of Wnt/beta-Catenin pathway in breast cancer[J]. Biomed Pharmacother, 2016, 84（期?）: 1144-1149. Li K,Ying M,Feng D,et al. Fructose-1,6-bisphosphatase is a novel regulator of Wnt/beta-Catenin pathway in breast cancer[J]. Biomed Pharmacother,2016,84:1144-1149.
[29]	Shi L,He C,Li Z,et al. FBP1 modulates cell metabolism of breast cancer cells by inhibiting the expression of HIF-1alpha[J]. Neoplasma,2017,64(4):535-542. doi: 10.4149/neo_2017_407
[30]	Fu D,Li J,Wei J,et al. HMGB2 is associated with malignancy and regulates Warburg effect by targeting LDHB and FBP1 in breast cancer[J]. Cell Commun Signal,2018,16(1):8-17. doi: 10.1186/s12964-018-0219-0
[31]	Shi L,Zhao C,Pu H,et al. FBP1 expression is associated with basal-like breast carcinoma[J]. Oncol Lett,2017,13(5):3046-3056. doi: 10.3892/ol.2017.5860
[32]	Chen J,Lee H-J,Wu X,et al. Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain[J]. Cancer Research,2015,75(3):554-565. doi: 10.1158/0008-5472.CAN-14-2268
[33]	Sheng H,Ying L,Zheng L,et al. Down expression of FBP1 is a negative prognostic factor for non-small-cell lung cancer[J]. Cancer Invest,2015,33(5):197-204. doi: 10.3109/07357907.2015.1020385
[34]	Zhang J,Wang J,Xing H,et al. Down-regulation of FBP1 by ZEB1-mediated repression confers to growth and invasion in lung cancer cells[J]. Mol Cell Biochem,2016,411(1):331-340.
[35]	Dong Y,Huaying S,Danying W,et al. Significance of methylation of FBP1 gene in non-small cell lung cancer[J]. Biomed Res Int,2018,2018(9):1-9.
[36]	Dai Q,Li N,Zhou X. Increased miR-21a provides metabolic advantages through suppression of FBP1 expression in non-small cell lung cancer cells[J]. Am J Cancer Res,2017,7(11):2121-2130.

相关文章(20)

[1]	刘孟雪, 缪佳, 盛雪鹤. 血UA、Smad1蛋白、尿mALB含量与2型糖尿病肾病患者达格列净治疗效果的相关性分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240425
[2]	王海军, 邱良武, 习杨彦彬, 庞俊娣. 有氧运动干预慢性脑缺血学习记忆能力研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240328
[3]	李婷, 郭维华. 糖酵解重编程在口腔鳞状细胞癌中的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230611
[4]	王群, 孙雨欣, 王海峰. 脂滴表面蛋白perilipin家族在癌症中的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230812
[5]	王英宝, 李晓云, 谭莹, 杨萌, 史云强, 平秦榕, 胡礼炳, 杨洋, 王春晖. 青蒿素调控ENO2介导的肾透明细胞癌细胞有氧糖酵解的机制, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231102
[6]	张玮, 王保全, 雷喜锋, 王旭, 张梁. miR-125b-5p调控HK2抑制胆囊癌细胞增殖和糖酵解, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20221206
[7]	曾怡, 廖云娟, 李颖, 何振坤. 达格列净治疗早期糖尿病肾病的疗效及对血清MCP-1、IL-6水平的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20211218
[8]	李晨, 马东艳, 李飞丽, 何敏, 杨娜, 麦晓蓉, 杨春梅. 基于表达性艺术治疗的女性癌症病房照护模式创新与实践, 昆明医科大学学报.
[9]	杨荆, 王淑娴, 周竹. 有氧运动与营养管理对维持性血透患者营养不良的疗效, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20201123
[10]	周灵, 左瑞玲, 马莉, 杨艳阳, 胡雪姣, 谢琳. 癌症患者化疗前焦虑对化疗后恶心呕吐的影响, 昆明医科大学学报.
[11]	吴江, 王云华, 姚丽琴, 费严焰, 谢杉, 石涛. 情境式健康教育模式在癌症患者疼痛教育中的应用, 昆明医科大学学报.
[12]	吴夕, 徐婷婷, 沈丽达, 谢琳, 胡凤娣, 龙庭凤, 董坚. 云南省贫困、偏远、少数民族聚集地区癌症相关危险因素现状调查, 昆明医科大学学报.
[13]	沈志祥, 朱立勋, 徐伟红. 有氧运动对2型糖尿病大鼠AGE-RAGE轴及NF-κB通路的影响, 昆明医科大学学报.
[14]	周玲, 钟琼, 王敏, 谭思, 刘永秀. 医联体医护一体化在癌症患者居家镇痛中的应用, 昆明医科大学学报.
[15]	朱宇, 何易晓, 杨丽娟, 王芳. 钙离子稳态失调与癌症增殖转移关系的研究进展, 昆明医科大学学报.
[16]	胡玉崇, 陆景坤, 崔梦瑶. PTEN及Caspase-3可能参与卵巢癌铂类耐药的机制, 昆明医科大学学报.
[17]	罗赛美. 癌症患者生命质量测定量表体系之前列腺癌量表QLICP-PR的条目筛选, 昆明医科大学学报.
[18]	张照莉. 癌症患者心理痛苦动态评估及干预的实践, 昆明医科大学学报.
[19]	李丹娜. 癌症患者生命质量的纵向研究现状, 昆明医科大学学报.
[20]	. 体外膜肺氧合与呼吸机治疗重症甲型H1N1流感病毒性肺炎体会, 昆明医科大学学报.